ReviewFrontiers in pharmacology2022
Aryl Hydrocarbon Receptor Mechanisms Affecting Chronic Kidney Disease.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 34 citations in OpenAlex.
- Oral Butyrate Reduces Progression of Kidney Damage in an L-NAME-Induced Diabetic Kidney Disease Mouse Model.Diabetes, obesity & metabolism · 2026Article
- Renal Tubular Epithelial Cells Senescence Induced by 1-Aminopyrene Activates Fibroblast via BRD4 Driven Senescence-Associated Secretory Phenotype Signaling.Journal of biochemical and molecular toxicology · 2026Article
- Role of the Gut-Liver-Kidney Axis in Disease Manifestation and Biomarker Alterations.International journal of molecular sciences · 2026Review
- Integrated Phytochemical, Network Pharmacology, and Molecular Docking Analyses of Triphala Extract Reveal Protective Effects Against HLife (Basel, Switzerland) · 2026Article
- Abatacept-Loaded Podocyte-Derived Exosomes Alleviate Membranous Nephropathy via AhR-Regulated NF-κB/Nrf2 Signaling under Oxidative Stress and Inflammation.Applied biochemistry and biotechnology · 2026Article
- AhR as a Common Denominator in Immunity and Inflammation in Chronic Lung Diseases: Molecular and Clinical Insights.Diseases (Basel, Switzerland) · 2026Review
- Review
- Propolis as a potential modulator of aryl hydrocarbon receptor signaling in inflammation.European cytokine network · 2026Review
- Selected tryptophan metabolites and inflammatory molecules in hemodialyzed patients.Pharmacological reports : PR · 2026Article
- Aryl hydrocarbon receptor-mediated transcriptional regulation of HSP70 exacerbates endoplasmic reticulum stress in lupus nephritis.Cell & bioscience · 2026Article
- Aryl Hydrocarbon Receptor (AhR) and Vascular Endothelial Growth Factor (VEGF) Crosstalk in Doxorubicin Nephrotoxicity: Mechanisms and Therapeutic Perspectives.Current issues in molecular biology · 2026Article
- Indoxyl sulfate in the gut-kidney axis: from diet-microbiome interactions to renal injury and targeted therapies.Frontiers in nutrition · 2026Review
- Altered tryptophan metabolism as a contributor to cognitive impairment in chronic kidney disease: a narrative review.Frontiers in neuroscience · 2026Review
- Fucoxanthin Ameliorates Diabetic Kidney Disease via Modulating the Gut Microbiota and Tryptophan-Kynurenine Metabolic Pathway.Journal of immunology research · 2026Article
- Targeting Tris(2,3-dibromopropyl) Isocyanurate-Induced Inflammation in Hippocampal Neurons In Vitro: Mechanistic Insights and Implications for Neurodegenerative Disease Prevention.Molecular neurobiology · 2025Article
- Modulation of the thiol redox proteome by sugarcane ash-derived silica nanoparticles: insights into chronic kidney disease of unknown etiology.Particle and fibre toxicology · 2025Article
- Telmisartan potentiates the ITE-induced aryl hydrocarbon receptor activity in human liver cell line.Archives of toxicology · 2025Article
- Gut microbiome remodeling in chronic kidney disease: implications of kidney replacement therapies and therapeutic interventions.Frontiers in medicine · 2025Review
- Bone Marrow Mesenchymal Stem Cells Can Prevent Pancreatic Fibrosis in Mice with Chronic Pancreatitis by Inhibiting the Activation of Pancreatic Stellate Cells.Journal of inflammation research · 2025Article
- The Impact of the Aryl Hydrocarbon Receptor on Antenatal Chemical Exposure-Induced Cardiovascular-Kidney-Metabolic Programming.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The aryl hydrocarbon receptor (AHR) is a basic helix-loop-helix transcription factor that binds diverse endogenous and xenobiotic ligands, which regulate AHR stability, transcriptional activity, and cell signaling. AHR activity is strongly implicated throughout the course of chronic kidney disease (CKD). Many diverse organic molecules bind and activate AHR and these ligands are reported to either promote glomerular and tubular damage or protect against kidney injury. AHR crosstalk with estrogen, peroxisome proliferator-activated receptor-γ, and NF-κB pathways may contribute to the diversity of AHR responses during the various forms and stages of CKD. The roles of AHR in kidney fibrosis, metabolism and the renin angiotensin system are described to offer insight into CKD pathogenesis and therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.